Physician profile
Adrian Sequeira
NPI 1366653057
$17,612.66
in general payments reported to CMS, 2019-2025
35 companies · $2,356 in 2025
The $2,356 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $472 · 2021: $976 · 2022: $771 · 2023: $3,804 · 2024: $8,066 · 2025: $2,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,054 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $3,581 · Consulting Fee: $938 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,054.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $3,581.32 |
| Consulting Fee | $937.50 |
| Education | $151.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,739.40 | 2021-2025 | Ellipsys Vascular Access System, In.Pact Av, In.Pact Admiral |
| Philips North America LLC | $1,007.16 | 2025 | Igt Devices Undivided, IV Other |
| Fresenius USA Marketing, INC. | $978.51 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $825.02 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $671.52 | 2019-2025 | Jynarque |
| Daiichi Sankyo INC. | $585.64 | 2019-2024 | Injectafer |
| Amgen INC. | $396.51 | 2019-2025 | Tavneos |
| W. L. Gore & Associates, INC. | $342.22 | 2023-2025 | Gore Viabahn Endoprosthesis With Heparin, Gore Viabahn Endoprosthesis |
| Travere Therapeutics, INC. | $311.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $275.50 | 2021-2024 | Jesduvroq |
| Nxstage Medical, INC. | $230.86 | 2022-2025 | Nxstage System One, Liberty Select Cycler |
| Mallinckrodt Hospital Products INC. | $223.64 | 2020-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $201.36 | 2022-2024 | Soliris, Ultomiris |
| Bard Peripheral Vascular, INC. | $199.21 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.58 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $154.89 | 2023-2024 | Jynarque |
| Recor Medical INC | $146.72 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cook Medical LLC | $139.80 | 2019-2023 | Performer |
| Novartis Pharmaceuticals Corporation | $139.49 | 2024-2025 | |
| Penumbra, INC. | $137.40 | 2025 | Penumbra System |
| Terumo Medical Corporation | $111.06 | 2022-2025 | Azur Cx Detachable, Angio-Seal |
| Aurinia Pharma U.S., INC. | $110.64 | 2021-2023 | Lupkynis |
| Allergan, INC. | $93.55 | 2019 | |
| Vifor Pharma, INC. | $88.32 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $74.46 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $46.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2021-2024 | Jardiance |
| Covidien Lp | $38.80 | 2019 | |
| Boston Scientific Corporation | $34.21 | 2022 | |
| Argon Medical Devices, INC. | $28.40 | 2024 | Clot Management |
| Microvention, INC. | $19.18 | 2020 | |
| Genzyme Corporation | $18.61 | 2019 | |
| Akebia Therapeutics INC | $16.06 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.04 | 2020 | |
| Genentech USA, INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Sequeira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.